
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
State asks High Court to reject challenge to anti-UNRWA laws ahead of Monday hearing - 2
Shadow Cats: The Elusive Leopards Surviving Against Impossible Odds - 3
Giude to Best Web based Learning Stage - 4
The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet - 5
Florence's Uffizi Gallery moves treasures to safety after cyberattack
New York to require social media platforms to display mental health warnings
The Force of Positive Reasoning: Day to day Attestations
Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
Planet-eating stars hint at Earth's ultimate fate
How to watch 'Tell Me Lies' Season 3: Episode release times, streaming info and more
6 Agreeable Earphones To Wear
U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
Manual for extravagance SUVs for seniors
Toddler diagnosed with cancer makes remarkable recovery after aggressive treatment













